Back to today’s briefing

Story perspectives

FDA Approves Breakthrough Blood Test for Alzheimer's Diagnosis

5/23/2025

34 7

Summary

Story summary

The FDA has greenlit the Lumipulse blood test, revolutionizing Alzheimer’s diagnosis with a less invasive option than PET scans. Targeting patients aged 55 and older, this test identifies amyloid plaques with an impressive 91.7% accuracy, paving the way for earlier diagnosis and better treatment access for nearly 7 million Americans battling this disease.

1 of 1

Story summary

The FDA has greenlit the Lumipulse blood test, revolutionizing Alzheimer’s diagnosis with a less invasive option than PET scans. Targeting patients aged 55 and older, this test identifies amyloid plaques with an impressive 91.7% accuracy, paving the way for earlier diagnosis and better treatment access for nearly 7 million Americans battling this disease.